Credit Suisse Ag Opti Nose, Inc. Transaction History

Credit Suisse Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 12, 2020	SELL	$3.58 - $7.44 $42,369 - $88,052	-11,835 Closed	0 $0
Q1 2020 May 13, 2020	BUY	$3.49 - $9.2 $2,631 - $6,936	754 Added 6.8%	11,835 $53,000
Q4 2019 Feb 12, 2020	SELL	$6.27 - $11.41 $27,625 - $50,272	-4,406 Reduced 28.45%	11,081 $103,000
Q3 2019 Nov 12, 2019	BUY	$4.75 - $8.38 $73,563 - $129,781	15,487 New	15,487 $108,000
Q3 2018 Nov 13, 2018	SELL	$12.43 - $29.76 $94,704 - $226,741	-7,619 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$18.75 - $28.46 $142,856 - $216,836	7,619 New	7,619 $213,000

88.3M

Ticker OPTN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 83,277,504
Market Cap $40M
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.